इसराइल - अंग्रेज़ी - Ministry of Health

bayer israel ltd - drospirenone; estradiol as hemihydrate - film coated tablets - drospirenone 2 mg; estradiol as hemihydrate 1 mg - estradiol - estradiol - angeliq is indicated for hormone replacement therapy (hrt) for estrogen deficiency symptoms in postmenopausal women more than 1 year post menopause. prevention of postmenopausal osteoporosis in women with an increased risk of future osteoporosis fractures.

इसराइल - अंग्रेज़ी - Ministry of Health

novartis israel ltd - dabrafenib as mesilate - hard capsule - dabrafenib as mesilate 50 mg - dabrafenib - dabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation.non-small cell lung cancer (nsclc) :dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a braf v600 mutation.adjuvant treatment of melanoma :dabrafenib in combination with trametinib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with braf v600 mutation, following complete resection.braf v600e mutation-positive locally advanced or metastatic anaplastic thyroid cancertafinlar is indicated, in combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (atc) with braf v600e mutation and with no satisfactory locoregional treatment optionsbraf v600e mutation-positive unresectable or metastatic solid tumorstafinlar is indicated, in combination with trametinib, for the treatment of adult and pediatric patients 6 years of age and older with unresectable or metastatic solid tumors with braf v600e mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. limitations of use: dabrafenib is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to braf inhibition. dabrafenib is indicated, in combination with trametinib, for the treatment of pediatric patients 6 year of age and older with low-grade glioma (lgg) with a braf v600e mutation who require systemic therapy

इसराइल - अंग्रेज़ी - Ministry of Health

novartis israel ltd - dabrafenib as mesilate - hard capsule - dabrafenib as mesilate 50 mg - dabrafenib - dabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation.non-small cell lung cancer (nsclc) :dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a braf v600 mutation.adjuvant treatment of melanoma : dabrafenib in combination with trametinib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with braf v600 mutation, following complete resection.braf v600e mutation-positive locally advanced or metastatic anaplastic thyroid cancertafinlar is indicated, in combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (atc) with braf v600e mutation and with no satisfactory locoregional treatment options

इसराइल - अंग्रेज़ी - Ministry of Health

novartis israel ltd - dabrafenib as mesilate - hard capsule - dabrafenib as mesilate 75 mg - dabrafenib - dabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation.non-small cell lung cancer (nsclc)dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a braf v600 mutation.adjuvant treatment of melanoma :dabrafenib in combination with trametinib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with braf v600 mutation, following complete resection.braf v600e mutation-positive locally advanced or metastatic anaplastic thyroid cancertafinlar is indicated, in combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (atc) with braf v600e mutation and with no satisfactory locoregional treatment optionsbraf v600e mutation-positive unresectable or metastatic solid tumorstafinlar is indicated, in combination with trametinib, for the treatment of adult and pediatric patients 6 years of age and older with unresectable or metastatic solid tumors with braf v600e mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. limitations of use: dabrafenib is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to braf inhibition. dabrafenib is indicated, in combination with trametinib, for the treatment of pediatric patients 6 year of age and older with low-grade glioma (lgg) with a braf v600e mutation who require systemic therapy

इसराइल - अंग्रेज़ी - Ministry of Health

abbott medical laboratories ltd, israel - dydrogesterone; estradiol; estradiol - film coated tablets - dydrogesterone 10 mg; estradiol 1 mg; estradiol 1 mg - dydrogesterone and estrogen - hormone replacement therapy (hrt) for estrogen deficiency symptoms in menopausal women at least 6 months since last menses.prevention of osteoporosis in postmenopausal women at high risk of future fractures. femoston 1/10 should only be used in patients who are intolerant of other products, approved for the prevention of osteoporosis or for whom these products are contra-indicated.femoston is indicated for women with an intact uterusexperience with treatment of women older than 65 years is limited.

इसराइल - अंग्रेज़ी - Ministry of Health

abbott medical laboratories ltd, israel - dydrogesterone; estradiol as hemihydrate - film coated tablets - dydrogesterone 2.5 mg; estradiol as hemihydrate 0.5 mg - dydrogesterone and estrogen - hormone replacement therapy (hrt) for estrogen deficiency symptoms in postmenopausal women at least 12 months since last menses.femoston is indicated for women with an intact uterus

इसराइल - अंग्रेज़ी - Ministry of Health

abbott medical laboratories ltd, israel - dydrogesterone; estradiol as hemihydrate - film coated tablets - dydrogesterone 5 mg; estradiol as hemihydrate 1 mg - dydrogesterone and estrogen - hormone replacement therapy (hrt) for estrogen deficiency symptoms in postmenopausal women at least 12 months since last menses.prevention of osteoporosis in postmenopausal women at high risk of future fractures. femoston contini 1/5 should only be used in patients who are intolerant of other products, approved for the prevention of osteoporosis or for whom these products are contra-indicated.femoston is indicated for women with an intact uterus

जॉर्डन - अंग्रेज़ी - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة مستودع الأدوية الأردني - the jordan drugstore co - cyproterone acetate 10 mg - 10 mg

जॉर्डन - अंग्रेज़ी - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع البتراء للمواد الطبية - petra drug store - triptorelin 3.75 mg - 3.75 mg

जॉर्डन - अंग्रेज़ी - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع ادوية السختيان - sukhtian group - adalimumab 40 mg/0.8ml - 40 mg/0.8ml